Lenalidomide for treating multiple myeloma after 1 prior treatment with bortezomib (part-review of TA171): evaluation report

Contents:

01 Consultee and commentator comments on the Appraisal Consultation Document from Celgene

02 Consultee and commentator comments on the Appraisal Consultation Document from Myeloma UK

03 Consultee and commentator comments on the Appraisal Consultation Document from the Royal College of Nursing

04 Consultee and commentator comments on the Appraisal Consultation Document from the UK Myeloma Forum

05 Consultee and commentator comments on the Appraisal Consultation Document from Janssen

06 Consultee and commentator comments on the Appraisal Consultation Document from the Department of Health

07 Comments on the ACD from Dr Faith Davies

08 ERG Critique

09 ERG Erratum to Critique

10 Additional document submitted by the manufacturer Celgene

 

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 29 July 2014